ADK-HUMAN: A Potential Drug Target and Biomarker (G132)

Target Name: ADK

NCBI ID: G132

Content of Review Report on ADK Target / Biomarker

ADK

ADK-HUMAN: A Potential Drug Target and Biomarker

Autophagy-mediated diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, are among the leading causes of human debility and mortality. The neurodegeneration that occurs in these diseases is characterized by the progressive loss of brain cells, which results in the degenerative changes observed in the affected individuals. One of the key factors underlying these diseases is the dysfunction of the autophagy pathway, which is the body's natural response to the availability of energy resources. Therefore, targeting the autophagy pathway and modulating its dysfunction have the potential to provide new therapeutic approaches for the treatment of these diseases.

ADK-HUMAN, short for autophagy-associated protein K67, is a protein that is expressed in the brain and is involved in the regulation of autophagy. It plays a crucial role in the formation and maintenance of dendrites, which are the extensions of neurons that receive signals from other neurons. The dysfunction of the autophagy pathway has been implicated in the development and progression of these neurodegenerative diseases. Therefore, targeting ADK-HUMAN with drugs that modulate its function may be a promising strategy for the treatment of these diseases.

The autophagy pathway is a complex intracellular signaling pathway that involves multiple interacting proteins. The key components of this pathway include the proteinLC3, which is involved in the formation of autophagosomes, and the proteinLC1, which is involved in the recruitment of autophagosomes to the endoplasmic reticulum. The dysfunction of these proteins has been implicated in the development of neurodegenerative diseases.

ADK-HUMAN is a protein that is expressed in the brain and is involved in the regulation of autophagy. It plays a crucial role in the formation and maintenance of dendrites, which are the extensions of neurons that receive signals from other neurons. The dysfunction of the autophagy pathway has been implicated in the development and progression of these neurodegenerative diseases. Therefore, targeting ADK-HUMAN with drugs that modulate its function may be a promising strategy for the treatment of these diseases.

One of the key features of ADK-HUMAN is its ability to interact with the proteinBeclin-1 (BECN1), which is a critical component of the autophagy pathway.Beclin-1 is a protein that is expressed in a variety of tissues, including the brain, and is involved in the formation of autophagosomes. The dysfunction of Beclin-1 has been implicated in the development and progression of neurodegenerative diseases.

In addition to its interaction with Beclin-1, ADK-HUMAN has also been shown to interact with the proteinP620, which is a key regulator of the autophagy pathway. P620 is a protein that is expressed in the brain and is involved in the formation and maintenance of autophagosomes. The dysfunction of P620 has also been implicated in the development and progression of neurodegenerative diseases.

The dysfunction of the autophagy pathway has been implicated in the development and progression of a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Therefore, targeting ADK-HUMAN and modulating its function may be a promising strategy for the treatment of these diseases.

In conclusion, ADK-HUMAN is a protein that is involved in the regulation of autophagy and has been implicated in the development and progression of a variety of neurodegenerative diseases. Targeting its function with drugs that modulate the autophagy pathway may be a promising strategy for the treatment of these diseases. Further research is needed to

Protein Name: Adenosine Kinase

Functions: Catalyzes the phosphorylation of the purine nucleoside adenosine at the 5' position in an ATP-dependent manner. Serves as a potential regulator of concentrations of extracellular adenosine and intracellular adenine nucleotides

The "ADK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets